Table 3.

Acute and late toxicity for patients with locally advanced cervical cancer who received whole pelvic radiotherapy concurrent with or without chemotherapy, followed by stereotactic body radiation therapy via helical tomotherapy

Toxicity*	Patients, n (%)
	Acute toxicity
	Nausea/vomiting	Diarrhea	Genitourinary effects	Body weight loss	Anemia	Leukopenia	Thrombocytopenia
Gr 1	9 (100)	7 (78)	8 (89)	10 (100)	8 (89)	8 (89)	6 (67)
Gr 2	0	1 (11)	1 (11)	0	1 (11)	1 (11)	2 (22)
Gr 3	0	1 (11)	0	0	0	0	1 (11)
Gr 4	0	0	0	0	0	0	0
Gr 5	0	0	0	0	0	0	0
Patient	Late toxicity
	Rectal bleeding			Genitourinary effects		Fistula formation
1	Grade 2 rectal bleeding Occurred in month 25			No occurrence until present (26 months)		No occurrence until present (26 months)
2	No occurrence until present (16 months)			No occurrence until present (16 months)		No occurrence until present (16 months)
3	No occurrence until present (12 months)			No occurrence until present (12 months)		No occurrence until present (12 months)
4	No occurrence until present (4 months)			No occurrence until present (4 months)		No occurrence until present (4 months)
5	Grade 2 rectal bleeding Occurred in month 11			No occurrence prior to expiration (13 months)		No occurrence prior to expiration (13 months)
6	Grade 2 rectal bleeding Occurred in month 14			No occurrence until present (40 months)		No occurrence until present (40 months)
7	No occurrence prior to expiration (10 months)			No occurrence prior to expiration (10 months)		No occurrence prior to expiration (10 months)
8	No occurrence prior to expiration (6 months)			No occurrence prior to expiration (6 months)		No occurrence prior to expiration (6 months)
9	No occurrence prior to expiration (10 months)			No occurrence prior to expiration (10 months)		Occurred in month 3

Notes:

^*The grade of toxicity followed the Common Terminology Criteria for Adverse Events (CTCAE) v 3.0.⁸